What You Should Know: - Tempus, an $8B precision medicine company, announced the launch of a new psychiatric real-world data program to leverage real-world data to inform mental health treatment. - Tempus N+ is a collaboration between provider institutions across the country and Tempus to build an infrastructure for data-driven research – providers can seamlessly and securely contribute molecular and clinical data, and in turn, their clinicians and researchers can access a
Read More
Real World Evidence (RWE)
Using NLP Technology To Uncover Real-World Patient Insights
It’s estimated that humans create a combined 2.5 quintillion bytes of data each day – and that around 90% of all data to ever exist was created in just the last few years. As difficult as it is to ignore the massive impact that connected technologies and social media have had on the way we experience our world, it’s somehow even more challenging to fully grasp the scale of it. For health researchers, this data explosion – and especially the rise
Read More
ConcertAI Raises $150M at $1.9 Billion Valuation for RWD Platform
What You Should Know: - ConcertAI, LLC (ConcertAI), the leader in enterprise AI and real-world data (RWD) solutions for life sciences and healthcare, announced the close of its $150M in Series C led by Sixth Street at a $1.9B valuation. - From its startup just five years ago, ConcertAI has emerged as one of the fastest-growing companies providing high-value software-as-a-service (SaaS) and data solutions to life sciences and biopharma companies, leading healthcare providers, contract
Read More
Implementing Responsible AI to Drive Innovation in Clinical Research & Precision Medicine
Researchers might be skeptical and, with people’s lives at stake, that’s understandable. Here’s how to take advantage of the advances while ensuring safeguards are in place. As artificial intelligence (AI) and machine learning drive innovation and disruption in clinical trials and precision medicine, questions around the responsible use of AI have moved to the forefront of debates among healthcare stakeholders – patients, providers, regulatory authorities, payors and sponsors. To what extent,
Read More
Aetion Acquires Synthetic Data Platform Replica Analytics
What You Should Know: - Aetion, a real-world evidence (RWE) tech platform, has just announced its acquisition of Replica Analytics, a pioneer in using ML to generate synthetic data. Financial details of the acquisition were not disclosed. - This acquisition allows Aetion to solve for one of the toughest problems in RWE: access to fit-for-purpose data. Synthetic data acts as a “digital clone” of real-world data by maintaining the source data’s statistical properties, while also protecting
Read More
Using Real-World Evidence (RWE) & AI to Enable Better Clinical Care
During the prescribing process, a physician’s ability to accurately and reliably match the most appropriate therapy option with the patient at hand is limited by the amount and quality of clinical information that is available. While randomized clinical trials are considered the gold standard for establishing the safety and efficacy of prescription medications, and the clinical findings verified from the trial inform the label on the approved therapy, the overall utility of such trials is
Read More
Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data
What You Should Know: - Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system. - Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities. Bringing Data-Driven Approach to
Read More
Using Machine Learning in the Evolving Landscape of Real-World Data
According to the Food and Drug Administration (FDA), the term real-world data (RWD) refers to routinely collected data relating to patient health status and the delivery of healthcare services, and real-world evidence (RWE) is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of RWD. Both RWD and RWE have increasingly attracted attention in the healthcare industry for years now, and rightly so, considering that the healthcare
Read More
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know: - Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care. - Ontada and Merck’s combined experience and
Read More
Vivalink Launches RWE Biometrics Data Platform
What You Should Know: - Vivalink, a provider of digital healthcare solutions for real-world evidence data, announced the launch of its enhanced Biometrics Data Platform to accelerate the development and deployment of patient monitoring and data analysis applications for ambulatory and remote settings. Vivalink’s Biometrics Data Platform completes the company’s end-to-end solution that includes both advanced data services as well as medical wearable sensors. The Biometrics Data Platform
Read More